It's going to be at least a couple of years before this company has recurring revenue from any commercial-stage products. While it makes sense for a billionaire like Ken Griffin to buy Viking Therapeutics stock at such a high valuation, most investors don't have his enormous risk...
However, Griffin was busy adding to Citadel's position in Charter. He increased his hedge fund's position in the stock by roughly 60.8% in Q3, owning 1.86 million shares at the end of the quarter. So far, Griffin's decision appears to be the smarter one. Charter's share pri...
Citadel Advisors, run by billionaire investor Ken Griffin, is one of the most prestigious hedge funds on Wall Street, and while reviewing the 13F it filed on Nov. 14, I noticed something. In the third quarter, the fund increased its stake by 172% in a semiconductor stock thatisn't...